Liu CH, et al. - In this work, the effectiveness and safety of sofosbuvir (SOF) combined with ledipasvir (LDV) or daclatasvir (DCV) were investigated in heart transplant recipients with chronic hepatitis C virus (HCV). Researchers observed sustained virologic response (SVR12) rate of 100%. All patients tolerated treatment well without interruption, death or serious adverse events.